<DOC>
	<DOCNO>NCT02264145</DOCNO>
	<brief_summary>The study objective determine effect ethanolic solution inhale Metered dose inhaler ( MDI ) ( 15.5 mg , 31.2 mg 62.4 mg ethanol ) Respimat速 ( 18.4 ethanol ) breath alcohol measurement healthy volunteer . Secondary aim determine linear dose-effect HFA 134a-MDI dos . An open , randomize , four-way-cross-over design chosen . The randomization balance stratified accordance predict value volunteer Total Lung Capacity ( TLC )</brief_summary>
	<brief_title>The Effect Alcoholic-carrier Solutions Within Devices ( HFA134a-MDI Respimat速 ) Breath Alcohol Measured Ethylometer Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy nonsmoker volunteer without dental prothesis 18 45 year old , male female No clinically significant abnormal condition screen visit . A clinically significant disease define one , opinion investigator , may either put subject risk participation study , disease may influence result study subject ability participate study Volunteer gammaglutamyltransferase ( GGT ) level &lt; 32 IU/L Volunteer able sign inform consent accordance Good Clinical Practice local legislation Volunteers able trained performance technically satisfactory pulmonary function test Volunteer able train correct use HFAMDI , Respimat速 Ethylometer Affiliated National Social Security System Subjects already take investigational drug take part another trial past month Consumption alcoholic beverage within 12 hour prior observation period Breast feeding pregnant female female medically approve contraception method ( oral contraceptive , intra uterine device ) Subjects know intolerance hypersensitivity aerosolize containing product and/or HFAMDI Respimat速 excipient Volunteer history drug abuse and/or alcoholism Intensive exercise one week prior study Major exposure dust , smoke pollution one week prior study Subjects upper low respiratory tract infection within previous four week screen . This insure reduce alcohol absorption mucus Current psychiatric disorder Previous inclusion randomize period study Subjects concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>